Hematologic Oncology

February 4, 2021 - The China National Medical Products Administration has granted a conditional approval to gilteritinib for use in adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation detected by a validated test.

In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020.

The landscape for pediatric oncology drugs expanded dramatically last year, with 8 new drugs or indications specifically approved for children compared with just 47 for treatment and supportive care products from the early 1950s through 2019.

Dr Stilgenbauer explains the ELEVATE-TN and ASCEND clinical trials; Dr Brown highlights the adverse effects seen with acalabrutinib.

Experts provide insight on the use of acalabrutinib in treating chronic lymphocytic leukemia.

Dr Brown provides a brief overview of data available that support the use of Bruton’s tyrosine kinase inhibitors in treating chronic lymphocytic leukemia; Dr Stilgenbauer comments on mitigating and managing adverse effects in the treatment of chronic lymphocytic leukemia.

Dr Ghia provides an in-depth conversation on the use of Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia.

February 2, 2021 - Emil J. Freireich, MD, DSc, a founding father of modern clinical cancer research and the 2015 Giants of Cancer Care award winner for Lymphoid Neoplasms, has died at age 93.

Marc J. Braunstein, MD, PhD, discusses the current landscape of newly diagnosed multiple myeloma and the utility of minimal residual disease in the research sphere.

February 1, 2020 - The European Medicines Agency’s Committee of Medicinal Products for Human Use has recommended a label expansion for pembrolizumab for use as a single agent in adult and pediatric patients aged 3 years and older with relapsed/refractory classical Hodgkin lymphoma for whom autologous stem cell transplant has failed or following at least 2 previous therapies when ASCT is not an option.

January 29, 2021 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for selinexor for use in combination with dexamethasone in the treatment of select adult patients with refractory multiple myeloma.

Elias Jabbour, MD, discusses the rationale to evaluate KO-539 in relapsed/refractory acute myeloid leukemia.